Ardelyx Schedules Second Quarter 2026 Financial Results Webcast for August 6, 2026
Ardelyx has scheduled a webcast and conference call for August 6, 2026, at 4:30 p.m. Eastern Time to present its second quarter 2026 financial results and business update. The event will be accessible live via the company's website, with a replay available post-event. The company currently markets two approved products in the United States — IBSRELA® and XPHOZAH® (both tenapanor) — and is advancing a pipeline that includes Phase 3 development of IBSRELA for chronic idiopathic constipation and RDX10531, a next-generation NHE3 inhibitor.
*this image is generated using AI for illustrative purposes only.
Ardelyx, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, has announced that its management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time. The event will cover financial results and a business update for the second quarter of 2026.
Event Access Details
Investors and interested parties can access the live webcast, along with accompanying slides, through the "Events and Presentations" section under "News and Events" within the Investors section of the company's website at www.ardelyx.com . An archived replay of the webcast and related presentation materials will be made available on the company's website following the event.
The conference call dial-in details are as follows:
| Parameter: | Details |
|---|---|
| Event Date: | Thursday, August 6, 2026 |
| Event Time: | 4:30 p.m. Eastern Time |
| Domestic (Toll-Free): | 877-346-6112 |
| International (Toll): | +1 848-280-6350 |
| Webcast: | www.ardelyx.com |
About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines addressing significant unmet medical needs. The company currently has two commercial products approved in the United States:
- IBSRELA® (tenapanor)
- XPHOZAH® (tenapanor)
The company's pipeline includes the following development programs:
- IBSRELA for chronic idiopathic constipation (CIC): Currently in Phase 3 development
- RDX10531: A next-generation NHE3 inhibitor with potential application across multiple therapeutic areas
Ardelyx also works with partners to develop and commercialize its products outside of the United States.
How might the Q2 2026 financial performance of IBSRELA and XPHOZAH influence Ardelyx's valuation ahead of potential market expansion?
What specific milestones or data readouts are expected from the Phase 3 trials for IBSRELA in chronic idiopathic constipation during the upcoming business update?
Will Ardelyx provide an updated timeline or new clinical targets for the next-generation NHE3 inhibitor RDX10531 in its multi-therapeutic area development program?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
